The CRADA partner contributes to all means necessary for the project, as well as to personnel, services, facilities, equipment or other resources. Additional annexes to reporting obligations or project-specific questions may also be added. CRADA offers the non-federal employee the opportunity to negotiate an exclusive or non-exclusive license for each CRADA Subject Invention resulting from the research. CRADA is the only agreement allowing an IP licensing option developed during a joint research project. CRADAs, which explicitly attempt to direct NIH research, are not appropriate. In addition, when considering a CRADA proposal, care should be taken to ensure that targeted research is implicitly the net effect. For example, the more resources a laboratory comes from a CRADA, the less likely it is that the laboratory will follow other research opportunities outside of CRADA; The wider the scope of a CRADA research plan, the less a laboratory will be able to offer equitable access and interact with others. The achievement of this balance shall be taken into account in the decision-making process. Important considerations should therefore be taken into account 1. CRADAs are only suitable for collaborators who make substantial intellectual contributions to the research project or who contribute to critical research materials or technical resources that are not otherwise available to the FDA. .